CytomX Therapeutics (CTMX) Current Assets (2016 - 2025)
Historic Current Assets for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $149.2 million.
- CytomX Therapeutics' Current Assets rose 2016.19% to $149.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $149.2 million, marking a year-over-year increase of 2016.19%. This contributed to the annual value of $107.3 million for FY2024, which is 4134.29% down from last year.
- CytomX Therapeutics' Current Assets amounted to $149.2 million in Q3 2025, which was up 2016.19% from $164.6 million recorded in Q2 2025.
- Over the past 5 years, CytomX Therapeutics' Current Assets peaked at $400.0 million during Q1 2021, and registered a low of $86.6 million during Q1 2025.
- In the last 5 years, CytomX Therapeutics' Current Assets had a median value of $200.3 million in 2022 and averaged $204.6 million.
- Data for CytomX Therapeutics' Current Assets shows a peak YoY increase of 2016.19% (in 2025) and a maximum YoY decrease of 4820.36% (in 2025) over the last 5 years.
- Over the past 5 years, CytomX Therapeutics' Current Assets (Quarter) stood at $310.3 million in 2021, then dropped by 23.59% to $237.1 million in 2022, then decreased by 22.85% to $182.9 million in 2023, then tumbled by 41.34% to $107.3 million in 2024, then surged by 39.06% to $149.2 million in 2025.
- Its Current Assets was $149.2 million in Q3 2025, compared to $164.6 million in Q2 2025 and $86.6 million in Q1 2025.